OpRegen Data Presented At ARVO. Lineage Cell Therapeutics presented data from the Phase 1/2a trial testing OpRegen, its retinal pigment epithelial cell transplantation for treating age-related macular degeneration (dry AMD). The data was presented at the Annual Meeting of the Association for Research in Vison and Ophthalmology, ARVO. The presentation added additional patient data from its last cohort, demonstrating safety, tolerability, and improvements in visual function and cellular structure.Additional Data From The Efficacy Cohort Was Presented. The Phase 1/2a trial is an open-label trial with three cohorts of 4 patients each receiving ascending doses to establish safety, then a fourth cohort of 12 patients to test efficacy. Patients in the updated presentation have been assessed at 12 months following OpRegen treatment, with some patients followed for up to 5 years. Read More >>